2249-28-7

Basic information

• Product Name: 4-(3-Trifuoromethyl)phenyl-4-piperidinol
• Synonyms: 4-(ALPHA,ALPHA,ALPHA-TRIFLUORO-M-TOLYL)-4-PIPERIDINOL;4-(3-(TRIFLUOROMETHYL)PHENYL)-4'-PIPERIDINOL;4-[3-(TRIFLUOROMETHYL)PHENYL]-4-PIPERIDINOL;4-(3-trifuoromethyl)phenyl-4-piperidinol;TIMTEC-BB SBB003184;4-Hydroxy-4(3-Trifluoromethylphenyl)Piperidine;4-(alpha,alpha,alpha-trifluoro-m-tolyl)piperidin-4-ol;4-(3-Trifluoromethylphenyl)-4'-hydroxypiperidine
• CAS NO: 2249-28-7
• Molecular Formula: C₁₂H₁₄F₃NO
• Molecular Weight: 245.24
• EINECS: 218-840-3
• Product Categories: Piperidine
• Mol File: 2249-28-7.mol
• Article Data: 4

Chemical Properties

• Melting Point: 91-95 °C
• Boiling Point: 301°C
• Flash Point: 136°C
• Appearance: Light beige/Fine Crystalline Powder
• Density: 1.253
• CAS DataBase Reference: 4-(3-Trifuoromethyl)phenyl-4-piperidinol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-Trifuoromethyl)phenyl-4-piperidinol(2249-28-7)
• EPA Substance Registry System: 4-(3-Trifuoromethyl)phenyl-4-piperidinol(2249-28-7)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 36/37/38-22
• Safety Statements: 37/39-26-36
• Hazardous Substances Data: 2249-28-7(Hazardous Substances Data)

Usage

Chemical Properties

LIGHT BEIGE FINE CRYSTALLINE POWDER

Uses

4-[3-(Trifluoromethyl)phenyl]-4-piperidinol can be used to synthesize antagonists for CCR1 receptor. It can also be used to synthesize (bisarylmethoxy)butylpiperidine analogues as neurotransmitter transporter inhibitors. It is also an intermediate for xaliproden [135354-02-8].

InChI:InChI=1/C11H14FNO.CHF2/c12-10-3-1-2-9(8-10)11(14)4-6-13-7-5-11;1-3-2/h1-3,8,13-14H,4-7H2;1H

Upstream product

• 401-78-5 3-bromo-1-trifluoromethylbenzene 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 634464-86-1 tert-butyl 4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinecarboxylate 

Downstream Products

• 1227860-94-7 C₂₈H₂₂F₆N₄O₃ 
• 1201633-39-7 2-chloro-1-[4-(3-trifluoromethylphenyl)-3,6-dihydro-2H-pyridin-1-yl]ethanone 
• 1290145-05-9 C₂₅H₂₇F₃N₄O₄S 
• 1257300-82-5 1-[(7-bromo-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl)carbonyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-ol 
• 1166991-42-9 1-((R)-3-(4-chlorophenoxy)-2-hydroxypropyl)-4-(3-(trifluoromethyl)phenyl)piperidin-4-ol 
• 6652-16-0 4-(3-trifluoromethyl-phenyl)-piperidine hydrochloride 
• 1085946-41-3 4-(4-(trifluoromethyl)phenyl)piperidin-4-ol hydrochloride 
• 62513-52-4 1-(4-fluoro-2-nitro-phenyl)-4-[4-hydroxy-4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-butan-1-one 
• 59002-16-3 1-[γ-(2-Methyl-4-fluorobenzoyl)propyl]-4-(3-trifluoromethylphenyl)-4-hydroxypiperidine 
• 71916-46-6 4-[3-(trifluoromethyl)phenyl]-4-hydroxy-1-[4-[[7-(trifluoromethyl)-4-quinolinyl]amino]benzoyl]piperidine 
• 65040-68-8 4-(3-(trifluoromethyl)phenyl)-1,2,3,6-tetrahydropyridine 
• 180156-94-9 (2S)-(-)-1-(4-indolyloxy)-3-(4-hydroxy-4-(3-trifluoromethylphenyl)piperidin-1-yl)-2-propanol ethanedioate 
• 188607-08-1 11-[4-Hydroxy-4-(3-trifluoromethylphenyl)piperidine-1-yl]-2-methyl-6,11-dihydrodibenzo[b,e] oxepine 
• 177172-38-2 (3RS,4RS)-4-(3-trifluoromethylphenyl)-piperidin-3-ol 

Relevant articles and documents

Structure-Based Design and Synthesis of Piperidinol-Containing Molecules as New Mycobacterium abscessus Inhibitors

Non-tuberculous mycobacterium (NTM) infections, such as those caused by Mycobacterium abscessus, are increasing globally. Due to their intrinsic drug resistance, M. abscessus pulmonary infections are often difficult to cure using standard chemotherapy. We previously demonstrated that a piperidinol derivative, named PIPD1, is an efficient molecule both against M. abscessus and Mycobacterium tuberculosis, the agent of tuberculosis, by targeting the mycolic acid transporter MmpL3. These results prompted us to design and synthesize a series of piperidinol derivatives and to determine the biological activity against M. abscessus. Structure-activity relationship (SAR) studies pointed toward specific sites on the scaffold that can tolerate slight modifications. Overall, these results identified FMD-88 as a new promising active analogue against M. abscessus. Also, we determined the pharmacokinetics properties of PIPD1 and showed that intraperitoneal administration of this compound resulted in promising serum concentration and an elimination half-life of 3.2 hours.

DIPHENYLBUTYPIPERIDINE AUTOPHAGY INDUCERS

Autophagy inducing compounds, methods of their preparation and use, and kits containg said compounds are disclosed herein.